Oncimmune Holdings PLC Andrew Millet appointed to the Board as CFO (3679H)
August 17 2016 - 1:01AM
UK Regulatory
TIDMONC
RNS Number : 3679H
Oncimmune Holdings PLC
17 August 2016
17 August 2016
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Andrew Millet appointed to the Board as Chief Financial
Officer
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, announces that it has appointed
Andrew Millet, BA MBA, FCA as an Executive Director and Chief
Financial Officer.
Andrew has held varied senior finance positions in both public
and private companies for over 20 years and has broad experience in
managing high growth businesses, fund raisings and corporate
governance. Prior to being appointed CFO of Oncimmune, Andrew held
the position of Company Secretary and since June of this year, he
has been acting interim CFO. Andrew trained as an accountant with
Stoy Hayward (now BDO) and is a registered auditor.
Geoffrey Hamilton-Fairley, CEO of Oncimmune commented: "We are
delighted that Andrew has accepted the position of CFO. Having
previously held the position of Company Secretary and interim CFO,
he is already very familiar with the Company and I am confident he
will provide solid financial guidance and support as we continue to
commercialise our EarlyCDT(R)-Lung test and complete the final
clinical validation stage of our EarlyCDT(R) liver and ovarian
tests."
Commenting on his appointment, Andrew Millet said: "I am very
pleased to accept the position of CFO and to continue to work with
the Oncimmune team. I have great belief in the autoantibody tests
that can detect cancer up to four years earlier than other methods
and look forward to playing a part in their continued success."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
- Full name and age: Andrew Millet (aged 48)
- Current Directorships:
-- Cyber-Duck Limited
-- Pinknews Media Group Limited
-- Voiceserve Inc
-- Wisteria Limited
-- Wisteria Formations Limited
- Past Directorships (within the previous 5 years)
-- Incremental Plus Limited (dormant - dissolved 14/10/2014)
-- Choices 4 All
-- Globex Data Limited (dormant - dissolved 24/4/2012)
-- Web 2 Innovation Limited (dormant - dissolved 23/10/2012)
-- Adaptive Affinity Limited
-- Mediteranean Energy & Petroleum Company Limited (dissolved 19/4/2016)
-- Activinstinct Limited
-- Azappy Limited
-- Unquoted Capital Limited (dissolved 10/3/2015)
-- Credit Rating Office Limited
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
Aim Rules for Companies.
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 145,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers, the National Health Service (NHS) Scotland ECLS study
of 12,000 high-risk smokers. EarlyCDT(R) tests for liver and
ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information visit www.oncimmune.com
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey
Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASFAEFMFMSEEA
(END) Dow Jones Newswires
August 17, 2016 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024